Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA

Vanda Pharmaceuticals Netherlands

Vanda Pharmaceuticals Netherlands B.V.

Vanda Pharmaceuticals Netherlands patent portfolio — 56 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
Status
Public
HQ
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded
2003
Employees
600
Programs
4
Drugs
9
Patents
56
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Vanda Pharmaceuticals Netherlands patents

56 pharmaceutical patents indexed for Vanda Pharmaceuticals Netherlands. 0 expire within 24 months.

Vanda Pharmaceuticals Netherlands has 56 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

56 patents

Patent portfolio

Page 1 of 2

  1. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12318375

    Method of treatment with tradipitant

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12201604

    Treatment of circadian rhythm disorders

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12049457

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11951097

    Methods of treating multiple sclerosis

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11918556

    Treatment of circadian rhythm disorders

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11918557

    Treatment of circadian rhythm disorders

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11850229

    Treatment of circadian rhythm disorders

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11833130

    Treatment of circadian rhythm disorders

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11826339

    Treatment of circadian rhythm disorders

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11786502

    Method of treatment

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11759446

    Liquid tasimelteon formulations and methods of use thereof

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11760740

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11633377

    Treatment of circadian rhythm disorders

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11566011

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11549147

    Treatment of atopic dermatitis with tradipitant

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11324735

    Method of treatment with tradipitant

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11285129

    Treatment of circadian rhythm disorders

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11266622

    Method of treatment

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11203581

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11202770

    Liquid tasimelteon formulations and methods of use thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11141400

    Method of treatment

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10987346

    Iloperidone for the treatment of schizophrenia

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10980770

    Treatment of circadian rhythm disorders

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10945988

    Treatment of circadian rhythm disorders

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10874659

    Iloperidone metabolite for use in the treatment of psychiatric disorders

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10829465

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10821099

    Use of tradipitant in motion sickness

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10772880

    Method of treatment with tradipitant

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10610511

    Method of treatment

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10610510

    Treatment of circadian rhythm disorders

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10611744

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10570453

    Method of predicting a predisposition to QT prolongation

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10563259

    Method of treatment based on polymorphisms of the KCNQ1 gene

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10463655

    Method of treatment with tradipitant

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10449176

    Treatment of circadian rhythm disorders

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10441580

    Iloperidone for the treatment of schizophrenia

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10376487

    Method of treatment

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10272076

    Methods for the administration of iloperidone

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10179119

    Method of treatment

    Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10149829

    Treatment of circadian rhythm disorders

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10071977

    Highly purifid pharmaceutical grade tasimelteon

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9855241

    Treatment of circadian rhythm disorders

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9730910

    Treatment of circadian rhythm disorders

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9549913

    Treatment of circadian rhythm disorders

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9539234

    Treatment of circadian rhythm disorders

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9157121

    Method of treatment based on polymorphisms of the KCNQ1 gene

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9138432

    Methods for the administration of iloperidone

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vanda Pharmaceuticals Netherlands have?

56 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vanda Pharmaceuticals Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.